Gilles Alberici has a 20-years experience in the European pharmaceutical industry.
Gilles obtained his PharmD. (1981) from Paris University, and then was resident and researcher in immunology in one of the French leading academic research hospital (Institut Gustave-Roussy) where he received his PhD (immunotoxicology).
Gilles is the author of more than 40 publications and 4 issued patents.
He served as Development and Manufacturing Director of biological agents in the Mérieux Group.
He founded and managed IMTIX in 1994, a Pasteur-Mérieux business unit dedicated to transplantation and haematology.
He was then President of IMTIX-SangStat, the European affiliate of SangStat, where he managed more than 140 people in 12 different countries.
Gilles founded OPi in September 1999, a pharmaceutical company dedicated to the development and marketing for rare and serious diseases for instance in onco-hematology.
He served as President and CEO of OPi SA and its subsidiaries which total sales went up to 18 M€ in 2006. OPi was sold to EUSA Pharma in march 2007.
Similary and in coherence with its public health strategy, Octalfa created Alberici-Octalfa foundation, which main mission is to help cancer patients and support projects that would improve their care.
Vincent Fert, Chief Executive Officer, Board member and Strategic Committee member
Vincent Fert has a master’s degree in immunology of the University of Marseilles, France.
Prior to founding Ipsogen in 1999, Vincent Fert held different executive positions at Immunotech. He was first responsible for R&D, then license acquisition and business development. Vincent is the author of 15 scientific publications and 9 patents.
After Immunotech was acquired by Beckman-Coulter (USA), in 1996, Vincent joined the ‘Advanced Technology Centre’ in Brea, CA where he led technology research projects.
In 1999, with Industry managers, scientists and physicians, Vincent founded Ipsogen, Marseilles, France to develop and market innovative diagnostic tools in order to tailor cancer treatments.
Stéphane Debono, Chief Operating Officer, Board member and Strategic Committee member
Stéphane Debono graduated at ESIM (now the Ecole Centrale Marseille) with a specialization in industrial computer science.
Prior to co-founding Ipsogen in 1999, Stéphane Debono worked as a bioinformatics and manufacturing engineer at Beckman Coulter, Immunotech for 2 years.
After 6 years as CTO in Bioinformatics and Administrative Manager, Stéphane is currently COO of the company, being responsible for the development, design, and improvement of the systems that create and deliver Ipsogen's products and services, including molecular diagnostic kits manufacturing. He is the director of the human resources department and manages the general operations of the company.
Guillaume Connan, Matignon Investissement & Gestion S.A ("MIG") permanent representative, Board member and Strategic Committee member
Guillaume Connan is graduated from HEC. He heads the participation departement at Matignon Technologies, one of the first european player in the field of innovative companies in technology and health services.
Guillaume Connan joined Matignon Technologies in 2000 and has invested in a wide range of life sciences companies: drug delivery and engineering, in vitro diagnostics, orthopaedics, CROs and DNA analysis.
Connan is also a MIG representative in Ipsogen, Mapi, Eurogenetec, Kadrige and Hospital devices board.
Before joining Matignon Technologies, Guillaume Connan worked as an analyst in Mergers & Acquisitions in charge of TMT (Technology, Media & Telecommunications) with J.P. Morgan & Co.
Kevin Rakin, Board member
Mr. Rakin has been a member of the Board of Directors of Ipsogen since March 24th 2006.
Kevin Rakin was appointed Chief Executive Officer of Advanced BioHealing in Feburary 2007.
From January 2006 to February 2007 he was Interim CEO of Advanced BioHealing and executive-in-residence at Canaan Partners, a leading American venture capital firm.
Mr. Rakin was also co-founder of Genaissance Pharmaceuticals, a Nasdaq company specialized in pharmacogenomics.
He was the Company’s CEO from august 2002 until is merger with Clinical Data, Inc in October 2005.
Mr. Rakin received a B.S. in Business and a M.S. in Finance from the Universityof Cape Town and a M.B.A. from Columbia University.
Kevin is also a board member at Omrix BioPharmaceuticals, Inc. and VION Pharmaceuticals, Inc., both quoted on Nasdaq stock exchange.
Jean-Yves Nothias, SG Asset Management Alternative Investments permanent representative, Board member
Jean-Yves Nothias, PhD, leads the Life Sciences Team at SGAM Alternative Investments. He oversees all portfolio companies and has made significant contributions by bringing in CEOs, syndicating financial rounds and providing strategic advice.
Previously, he was a biotechnology analyst for Hambrecht & Quist based in Paris. He worked at F. Hoffmann-La Roche (US) and several scientific institutions in France and in the US.
Jean-Yves holds a PhD in molecular biology from Université Paris VI and a masters degree in management from Université Paris Sorbonne
Russell Tweeddale, Censor
Russell tweeddale has been Ipsogen’s censor since the 20th March 2008.
Russell is also investment director with Connecticut Innovations since 1985.
Russell has spent his career at CI as a member of the “deal team” reviewing and managing a multitude of investments in the biotechnology field and medical devices.
He has also been board member or censor for Cardium Health Services, Genaissance Pharmaceuticals, Achillion Pharmaceuticals, Rib-X Pharmaceuticals and Sopherion Therapeutics.
Prior to joining CI, Russell spent 20 years in various positions with United Technologies Corp. He has a background in economic and venture analysis, engineering cost accounting and systems analysis.
Russ earned a bachelor’s degree in electrical engineering and a master’s degree in business administration from the University of Hartford.
